Previous 10 | Next 10 |
Nova LifeStyle (NVFY) +231%.Siebert Financial (SIEB) +63% on Q4 results.Vir Biotechnology (VIR) +60% as its and GSK's COVID-19 antibody drug reduces hospitalization, death by 85%.OrganiGram Holdings (OGI) +40% on cannabis product deal with British American Tobacco.China HGS Rea...
AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA ® (tivozanib). FOTIVDA is AVE...
- FOTIVDA is the First Therapy Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies - - AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 - - Company to...
AVEO Pharmaceuticals ([[AVEO]] +70.7%) has surged following reports of FDA approval for tivozanib (FOTIVDA) for the treatment of relapsed or refractory renal cell carcinoma.FOTIVDA, a vascular endothelial growth factor receptor tyrosine kinase inhibitor is approved in the EU, the U.K., Norway...
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time. A live webcast of t...
– Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST Quality of Life Measure Shows Significant Improvement for Tivozanib over Sorafenib – AVEO Oncology ...
AVEO Oncology (AVEO) has received a commitment letter for an incremental $10M loan from Hercules Capital, to be added to the current tranched, $35M debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement.Under the terms o...
– $20M Tranche Available on Approval of Tivozanib – AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, ...
Aveo Oncology (AVEO) has announced results from the Phase 1b portion of Phase 1b/2 DEDUCTIVE trial, evaluating tivozanib (Fotivda), in combination with AstraZeneca's Imfinzi (durvalumab), in patients with advanced or metastatic hepatocellular carcinoma. Data were presented at the 2021 A...
– Data Presented at the 2021 ASCO GI Cancers Symposium – AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA ® ), AVEO’s vascular end...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...